论文部分内容阅读
用ＯＲＦ２、ＯＲＦ３合成肽抗原（１～１０号）及基因工程重组的ＯＲＦ２抗原（１和２号）分别建立了酶联免疫方法（ＥＩＡ），检测６０份戊型肝炎病人血清中ＨＥＶＩｇＧ及ＩｇＭ１０个合成肽抗原（Ｓｐ１－Ｓｐ１０）及２个重组抗原（Ｒｅ１、Ｒｅ２），均和ＨＥＶ阳性血清发生特异反应，但阳性率和反应强度差别很大。以Ｒｅ１（ＯＲＦ２，４０２～６６０）检测的抗体阳性率最高，为９６．７％（５８／６０）；Ｓｐ６（ＯＲＦ３，８８～１２３）次之，为９３．３％（５６／６０）；以上两种抗原混合使用阳性率为１００％（６０／６０）。Ｓｐ６、Ｒｅ１及这两种抗原混合使用检测抗ＨＥＶＩｇＭ，阳性率分别为１８．３％（１１／６０）、６６．７％（４０／６０）和６６．７％（４０／６０）。研究结果表明：合成肽６号（Ｓｐ６）及重组抗原１号（Ｒｅ１）是制备戊肝抗体诊断试剂的理想抗原。
Enzyme linked immunosorbent assay (EIA) was established with ORF2, ORF3 synthetic peptide antigen (No.10) and genetically engineered recombinant ORF2 antigen (No. 1 and No. 2), respectively, and 60 HEVgG and IgM Synthetic peptide antigen (Sp1-Sp10) and two recombinant antigens (Re1, Re2), and HEV-positive serum specific reaction, but the positive rate and the intensity of the reaction varies widely. The positive rate of antibody detected by Re1 (ORF2, 402 ~ 660) was 96.7% (58/60), followed by that of Sp6 (ORF3,88 ~ 123), followed by 93.3% (56/60) The positive rate of the two antigens is 100% (60/60). Sp6, Re1 and anti-HEVIgM in combination with these two antigens. The positive rates were 18.3% (11/60), 66.7% (40/60) and 66.7% (40/60), respectively. The results showed that the synthetic peptide 6 (Sp6) and recombinant antigen 1 (Re1) are ideal antigens for the preparation of hepatitis E antibody diagnostic reagents.